Works in Diabetology & Metabolic Syndrome, 2022, Vol 14, Issue 1


Results: 205
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.

    Published in:
    Diabetology & Metabolic Syndrome, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13098-022-00951-5
    By:
    • Gohari, Sepehr;
    • Reshadmanesh, Tara;
    • Khodabandehloo, Hadi;
    • Karbalaee-Hasani, Amir;
    • Ahangar, Hassan;
    • Arsang-Jang, Shahram;
    • Ismail-Beigi, Faramarz;
    • Dadashi, Mohsen;
    • Ghanbari, Samin;
    • Taheri, Homa;
    • Fathi, Mojtaba;
    • Muhammadi, Muhammad Javad;
    • Mahmoodian, Reyhaneh;
    • Asgari, Atieh;
    • Tayaranian, Mohammadreza;
    • Moharrami, Mehdi;
    • Mahjani, Mahsa;
    • Ghobadian, Bijan;
    • Chiti, Hossein;
    • Gohari, Sheida
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50